MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial

DNA repair is a double-edged sword in lung carcinogenesis. When defective, it promotes genetic instability and accumulated genetic alterations. Conversely these defects could sensitize cancer cells to therapeutic agents inducing DNA breaks. We used immunohistochemistry (IHC) to assess MSH2, XRCC5, a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2017-01, Vol.8 (3), p.4313-4329
Hauptverfasser:	Levallet, Guénaëlle, Dubois, Fatéméh, Fouret, Pierre, Antoine, Martine, Brosseau, Solenn, Bergot, Emmanuel, Beau-Faller, Michèle, Gounant, Valérie, Brambilla, Elisabeth, Debieuvre, Didier, Molinier, Olivier, Galateau-Sallé, Françoise, Mazieres, Julien, Quoix, Elisabeth, Pujol, Jean-Louis, Moro-Sibilot, Denis, Langlais, Alexandra, Morin, Franck, Westeel, Virginie, Zalcman, Gérard
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Biochemistry, Molecular Biology BRCA1 Protein - metabolism Cancer Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism DNA Methylation DNA Modification Methylases - genetics DNA Repair DNA Repair Enzymes - genetics Drug Therapy Female Gene Expression Regulation, Neoplastic Genomics Human health and pathology Humans Ku Autoantigen - metabolism Life Sciences Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Male Middle Aged MutS Homolog 2 Protein - metabolism Neoadjuvant Therapy Neoplasm Staging Prognosis Promoter Regions, Genetic Prospective Studies Pulmonology and respiratory tract Research Paper Survival Analysis Tumor Suppressor Proteins - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!